Cellebrite DI Ltd. (NASDAQ:CLBT) Short Interest Update

Cellebrite DI Ltd. (NASDAQ:CLBT) saw a large growth in short interest in March. As of March 15th, there was short interest totalling 1,280,000 shares, a growth of 19.6% from the February 28th total of 1,070,000 shares. Currently, 1.2% of the shares of the stock are short sold. Based on an average daily volume of 1,830,000 shares, the short-interest ratio is currently 0.7 days.

Cellebrite DI Stock Up 3.6 %

NASDAQ:CLBT traded up $0.70 on Wednesday, hitting $19.95. The stock had a trading volume of 431,363 shares, compared to its average volume of 1,392,915. The company has a fifty day moving average price of $20.71 and a two-hundred day moving average price of $19.94. Cellebrite DI has a 1-year low of $10.25 and a 1-year high of $26.30. The stock has a market cap of $4.78 billion, a price-to-earnings ratio of -14.35, a PEG ratio of 4.27 and a beta of 1.52.

Cellebrite DI (NASDAQ:CLBT) last released its quarterly earnings data on Thursday, February 13th. The company reported $0.07 EPS for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). Cellebrite DI had a negative net margin of 70.54% and a positive return on equity of 58.70%. As a group, analysts anticipate that Cellebrite DI will post 0.3 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. JPMorgan Chase & Co. increased their target price on shares of Cellebrite DI from $24.00 to $28.00 and gave the company an “overweight” rating in a research report on Tuesday, February 11th. Lake Street Capital increased their price objective on shares of Cellebrite DI from $17.00 to $26.00 and gave the company a “buy” rating in a report on Friday, February 14th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $28.00 target price on shares of Cellebrite DI in a research note on Wednesday. Seven analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $23.43.

Hedge Funds Weigh In On Cellebrite DI

A number of hedge funds have recently modified their holdings of CLBT. Axon Enterprise Inc. acquired a new stake in shares of Cellebrite DI during the fourth quarter valued at about $198,270,000. FMR LLC boosted its position in shares of Cellebrite DI by 89.1% during the 4th quarter. FMR LLC now owns 10,621,344 shares of the company’s stock worth $233,988,000 after purchasing an additional 5,004,587 shares during the period. True Wind Capital Management L.P. increased its holdings in Cellebrite DI by 18.2% in the 4th quarter. True Wind Capital Management L.P. now owns 13,861,007 shares of the company’s stock valued at $305,358,000 after purchasing an additional 2,130,386 shares during the last quarter. Invesco Ltd. purchased a new stake in Cellebrite DI in the fourth quarter valued at approximately $32,700,000. Finally, Principal Financial Group Inc. acquired a new position in Cellebrite DI during the third quarter worth $23,402,000. 45.88% of the stock is currently owned by hedge funds and other institutional investors.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.